Skip to main content
. 2015 May 13;9(5):665–671. doi: 10.5009/gnl14212

Fig. 1.

Fig. 1

The 5805 peak profiling in the control, liver fibrosis (LF), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) groups showed that the intensity of the 5805 peak was much higher in the LC and HCC groups. The 5805-Da protein is a potential biomarker for differentiating LC from stage IV fibrosis and predicting the progression of hepatitis B virus-related liver diseases.